February 26, 2007 — A blood test for C-reactive protein (CRP), which is readily available and already used to assess the risk of cardiovascular disease, could be useful in predicting prognosis for men ...

Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, research has demonstrated that combining ADT with additional agents ...

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...

The Bellmunt Risk Score can provide prognostic information on survival among patients with metastatic castration-resistant prostate cancer, new data suggest.

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...

A new drug combination may benefit men whose prostate cancer has returned after primary surgery or radiation therapy. Pairing enzalutamide, an androgen receptor blocker, with the hormone therapy drug ...

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...

Pooled trials show Pluvicto improves progression-free survival in advanced prostate cancer, without increasing serious adverse events. An examination of data from more than 2500 patients with advanced ...

(A) Expression density map of single-cell sequencing cell typing in prostate cancer. (B) UMAP diagram of RAB26 in prostate cancer cells. (C) Expression of RAB26 in different cell types. (D) Expression ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...